ProGen Co., Ltd. is a biotechnology company, which engages in the research and development of antibody therapeutics. It offers Neo Tri-ImmunoGlobulin (NTIG), a platform technology optimized for the development of anti-cancer and immune disease treatments. The company was founded on October 21, 1998 and is headquartered in Seoul, South Korea.